Orchid Pharma’s ‘Exblifep’ receives USFDA approval: A new milestone for India’s Pharmaceutical industry
Bse notification by Orchid
Orchid Pharma’s ‘Exblifep’ receives USFDA approval: A new milestone for
India’s Pharmaceutical industry
- Orchid is the first Indian company to have invented a product approved under the
New Drug Application (NDA) process by USFDA - The European Medicines Agency granted Exblifep approval in January 2024
New Delhi, 23 February 2024: Orchid Pharma, based in Chennai, India, has received approval by the
United States Food and Drug Administration (USFDA) for its novel invention, ‘Enmetazobactam’. This
development comes in close succession to the recent recommendation for approval by the European
Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase
Inhibitor.
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA.
| Subscribe To Our Free Newsletter |
